Adding ultrasound and/or tomosynthesis to digital mammography increases cancer detection.
Adding ultrasound (US) or digital breast tomosynthesis (DBT), or both, to digital mammography (DM) can increase rate of cancer detection not seen on conventional DM, according to a study published Acta Radiologica.
Researchers from Spain performed a retrospective study to assess the diagnostic performance of DM and the different combinations of additional US and DBT.
A 1,042-patient sample was used for the study. All patients had undergone DM, US, and DBT imaging. A total of 84 patients had histologically proven malignant lesions and 258 patients had benign lesions; 700 patients had normal findings or benign lesions without biopsy confirmation.
The results showed that the sensitivity and specificity of DM alone were 69.05% and 88.20%, respectively. With addition of DBT, there was a significant increase in the AUC of DM. This was also found with addition of US, as well as adding both US and DM. However, there were no significant differences seen between DM plus DBT and DM plus US.
“Additional US is a widespread used and well tolerated technique,” the authors wrote. “US can be used as a problem-solving technique after DM or magnetic resonance imaging, because it can offer information about the features of a lesion (solid-cystic differentiation, suspicious signs, and so on) and it is very useful for guiding interventional procedures.”
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.